Merck & Company Inc (MRK)vsUniverse Pharmaceuticals Inc (UPC)
MRK
Merck & Company Inc
$112.16
+2.73%
HEALTHCARE · Cap: $274.03B
UPC
Universe Pharmaceuticals Inc
$3.21
-0.60%
HEALTHCARE · Cap: $1.74M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 363930% more annual revenue ($65.01B vs $17.86M). MRK leads profitability with a 28.1% profit margin vs -20.6%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
UPC
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-16.2%
Fair Value
$96.56
Current Price
$112.16
$15.60 premium
Intrinsic value data unavailable for UPC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Smaller company, higher risk/reward
ROE of -7.2% — below average capital efficiency
Revenue declined 14.1%
Earnings declined 82.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : UPC
The strongest argument for UPC centers on Price/Book, Altman Z-Score, Debt/Equity.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : UPC
The primary concerns for UPC are Market Cap, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
MRK profiles as a value stock while UPC is a turnaround play — different risk/reward profiles.
UPC carries more volatility with a beta of 1.48 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 29/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Universe Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Universe Pharmaceuticals INC, a pharmaceutical company, is engaged in the manufacture, marketing, distribution and sale of products derived from traditional Chinese medicine in China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?